Abstract:AbstractPurposePrevious studies from our lab utilized an ultra-high throughput screening method to identify compound 1 as a small molecule that binds to alpha-synuclein (α-synuclein) fibrils. The goal of the current study was to conduct a similarity search of 1 to identify structural analogs having improved in vitro binding properties for this target that could be labeled with radionuclides for both in vitro and in vivo studies for measuring α-synuclein aggregates.MethodsUsing 1 as a lead compound in a similarity search, isoxazole derivative 15 was identified to bind to α-synuclein fibrils with high affinity in competition binding assays. A photocrosslinkable version was used to confirm binding site preference. Derivative 21, the iodo-analog of 15, was synthesized, and subsequently radiolabeled isotopologs [125I]21 and [11C]21 were successfully synthesized for use in in vitro and in vivo studies, respectively. [125I]21 was used in radioligand binding studies in post-mortem Parkinson’s disease (PD) and Alzheimer’s disease (AD) brain homogenates. In vivo imaging of an α-synuclein mouse model and non-human primates was performed with [11C]21.ResultsIn silico molecular docking and molecular dynamic simulation studies for a panel of compounds identified through a similarity search, were shown to correlate with Ki values obtained from in vitro binding studies. Improved affinity of isoxazole derivative 15 for α-synuclein binding site 9 was indicated by photocrosslinking studies with CLX10. Design and successful (radio)synthesis of iodo-analog 21 of isoxazole derivative 15 enabled further in vitro and in vivo evaluation. Kd values obtained in vitro with [125I]21 for α-synuclein and Aβ42 fibrils were 0.48 ± 0.08 nM and 2.47 ± 1.30 nM, respectively. [125I]21 showed higher binding in human postmortem PD brain tissue compared with AD tissue, and low binding in control brain tissue. Lastly, in vivo preclinical PET imaging showed elevated retention of [11C]21 in PFF-injected mouse brain. However, in PBS-injected control mouse brain, slow washout of the tracer indicates high non-specific binding. [11C]21 showed high initial brain uptake in a healthy non-human primate, followed by fast washout that may be caused by rapid metabolic rate (21% intact [11C]21 in blood at 5 min p.i.).ConclusionThrough a relatively simple ligand-based similarity search, we identified a new radioligand that binds with high affinity (<10 nM) to α-synuclein fibrils and PD tissue. Although the radioligand has suboptimal selectivity for α-synuclein towards Aβ and high non-specific binding, we show here that a simple in silico approach is a promising strategy to identify novel ligands for target proteins in the CNS with the potential to be radiolabeled for PET neuroimaging studies.

The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils

Structural characterisation of α-synuclein -membrane interactions and the resulting aggregation using small angle scattering

Binding adaptability of chemical ligands to polymorphic α-synuclein amyloid fibrils

Structural mechanism for specific binding of chemical compounds to amyloid fibrils

Mechanism of action deconvolution of the small-molecule pathological tau aggregation inhibitor Anle138b

Conformation-specific Binding of α-Synuclein to Novel Protein Partners Detected by Phage Display and NMR Spectroscopy

Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors

Elucidating the mechanisms of α-Synuclein-lipid interactions using site-directed mutagenesis

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Conformation-specific binding of alpha-synuclein to novel protein partners detected by phage display and NMR spectroscopy.

Identification of a Novel Parallel Β‐strand Conformation Within Molecular Monolayer of Amyloid Peptide

Probing the molecular mechanisms of α-synuclein inhibitors unveils promising natural candidates through machine-learning QSAR, pharmacophore modeling, and molecular dynamics simulations

Conformational equilibria in monomeric alpha-synuclein at the single molecule level

Molecular mechanism of α-synuclein aggregation on lipid membranes revealed

A targetable N-terminal motif orchestrates α-Synuclein oligomer to fibril conversion

Global kinetic model of lipid-induced alpha-synuclein aggregation and its inhibition by small molecules

Identification of a Putative α-synuclein Radioligand Using an in silico Similarity Search

Conformational Selection of α-Synuclein Tetramers at Biological Interfaces

Conformational Dynamics of an α-Synuclein Fibril upon Receptor Binding Revealed by Insensitive Nuclei Enhanced by Polarization Transfer-Based Solid-State Nuclear Magnetic Resonance and Cryo-Electron Microscopy

Selectivity of Protein Interactions along the Aggregation Pathway of α-Synuclein

Discovery of Styrylaniline Derivatives As Novel Alpha-Synuclein Aggregates Ligands.